- TriState Capital (NASDAQ:TSC) +29% on Q3 earnings.
- Atreca (NASDAQ:BCEL) +18% enters into licensing agreement with Bill & Melinda Gates Medical Research Institute to develop a monoclonal antibody for the prevention of malaria
- NextPlay Technologie (NASDAQ:NXTP) +20% on FQ2 earnings.
- Ra Medical Systems (NYSE:RMED) +15%.
- Sio Gene Therapies (NASDAQ:SIOX) +13% after interim data from early-stage AXO-AAV-GM1 trial
- Fangdd Network (NASDAQ:DUO) +14%.
- InnSuites Hospitality Trust (NYSE:IHT) +12% on Q2 earnings.
- Biotricity (NASDAQ:BTCY) +11%.
- Sesen Bio (NASDAQ:SESN) +10%.
- Crocs (NASDAQ:CROX) +10% on Q3 earnings.
- Kadmon Holdings (NASDAQ:KDMN) +9%.
- FTC Solar (NASDAQ:FTCI) +9%.
- ESS Tech (NYSE:GWH) +8%.
- Chemomab Therapeutics (NASDAQ:CMMB) +7%.
- Tiziana Life Sciences (NASDAQ:TLSA) +7% share capital consolidation and commencement of trading in the New Tiziana shares on NASDAQ
- China Finance Online (NASDAQ:JRJC) +7%.
- InMed Pharmaceuticals (NASDAQ:INM) +7%.
- Valneva (NASDAQ:VALN) +7%.
- Sentage (NASDAQ:SNTG) +7%.
- SGOCO (NASDAQ:SGOC) +6%.
- Intellia Therapeutics (NASDAQ:NTLA) +5% receives U.S. FDA orphan drug designation for NTLA-2001, an investigational CRISPR therapy for the treatment of transthyretin amyloidosis
- Dunxin Financial (NYSE:DXF) +6%.